Massachusetts-based Augmenix is hoping it can make it to the U.S. market with the $10.8 million funding round it just closed, the company said this month.
Radiosurgery/Radiation therapy
Elekta eyes Turkish radiology market with acquisition of Mesi Medikal
Revenue surge helps Accuray narrow Q3 losses, update full-year outlook
Patent battle takes a chunk out of Varian’s bottom line
Radiosurgery devices maker Varian Medical (NYSE:VAR) posted a tough quarter, with sales up a modest 1.3% and earnings sucked up by legal charges in its 2nd quarter.
Varian settles patent beef with Pitt for $35M
Varian Medical (NYSE:VAR) said it settled its patent infringement beef with the University of Pittsburgh for $35 million, after a federal appeals court overturned a portion of the $100 million award Pitt won in 2012.
Cancer: RefleXion Medical raises $11.6M to ‘make radiotherapy personal’
California-based medtech group RefleXion Medical touted an $11.6 million Series A fundraising round, hoping to use the new funds to expand research & development efforts for its guided radiation therapy technology.
Halt Medical raises $92.8M ahead of U.S. launch of uterine fibroid treatment
California women’s health company Halt Medical is raising capital ahead of a major commercial bid for its Acessa radiofrequency-based uterine fibroid treatment.
AMIC looks to down-classify brachytherapy’s FDA status
Washington-based Advanced Medical Isotope Corp. is evaluating its options for U.S. market approval of its proprietary brachytherapy cancer product, the company announced.
Accuray notches win in trade secrets row with former supplier
Varian misses analysts’ estimates but is on track for 2014
Palo Alto, Calif.-based Varian Medical (NYSE:VAR) started its fiscal year with moderate growth and a reaffirmed outlook on 2014, but per-share earnings fall short of analysts’ projections.